Medpace Holdings Inc ((MEDP)), Radiopharm Theranostics Limited ((AU:RAD)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medpace Holdings Inc. and Radiopharm Theranostics Limited are collaborating on a Phase 2b study titled An Open-Label, Single Dose, Single Arm, Multicenter Phase 2b Study to Establish the Imaging Performance of RAD101 Positron Emission Tomography (PET) in Participants With Suspected Recurrent Brain Metastases From Solid Tumors. The study aims to evaluate the effectiveness of RAD101 PET imaging in detecting recurrent brain metastases, which could significantly impact diagnostic approaches for patients with solid tumors.
The intervention being tested is RAD101, an experimental drug administered as a single dose of 18F-Fluorescence polarization immunoassay (FPIA). This drug is intended to enhance PET imaging for better detection of brain metastases.
The study follows an interventional design with a single-group model, focusing on diagnostic purposes. It is open-label, meaning no masking is involved, allowing all participants and researchers to know the treatment being administered.
The study began on December 19, 2024, with a recent update on September 15, 2025. The primary completion and estimated study completion dates have not been disclosed, but the study is currently recruiting participants.
This clinical study update could influence the stock performance of both Medpace and Radiopharm Theranostics by potentially enhancing their market position in diagnostic imaging. Positive results could boost investor confidence and position these companies favorably against competitors in the imaging and diagnostics industry.
The study is ongoing, with further details available on the ClinicalTrials portal.